drugset / Trial / NCT07079475
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment
Timeline
- Start
- 2025-07-30
- Primary completion
- 2028-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DZD6008 | Unknown | 40 mg | Oral |
| Subject | DZD6008 | Unknown | 60 mg | Oral |
| Comparator | Osimertinib | Small molecule | 80 mg | Oral |
| Subject | Sunvozertinib | Small molecule | 100 mg | Oral |
| Subject | Sunvozertinib | Small molecule | 200 mg | Oral |